CA3016383A1 — Treating ephrin receptor a2 (epha2) positive cancer with targeted docetaxel-generating nano-liposome compositions

USPTO Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/161071 Al 21 September 2017 (21.09.2017) WIPO I PCT (51) International Patent Classification: (74) Agent: DAY PH.D., Noel E.; Honigman Miller Schwartz A61K 47/69 (2017.01) & Cohn LLP, 350 East Michigan Avenue, Suite 300, Kala-mazoo, Michigan 49007 (US). (21) International Application Number: PCT/US2017/022629 (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, 16 March 2017 (16.03.2017) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (25) Filing Language: English DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (26) Publication Language: English KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (30) Priority Data: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 62/309,240 16 March 2016 (16.03.2016) US NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, 62/322,991 15 April 2016 (15.04.2016) US RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, 62/419,047 8 November 2016 (08.11.2016) US TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, 62/464,574 28 February 2017 (28.02.2017) US ZA, ZM, ZW. (71) Applicant: MERRIMACK PHARMACEUTICALS, (84) Designated States (unless otherwise indicated, for every INC [US/US]; One Kendall Square, Suite B7201, Cam-kind of regional protection available): ARIPO (BW, GH, bridge, Massachusetts 02139 (US). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (72) Inventors: DRUMMOND, Daryl C. 1 Brooks Road, Lin-TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, cohi, Massachusetts 01773 (US). KAMOUN, Walid; 7 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Wollaston Avenue, Arlington, Massachusetts 02476 (US). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). [Continued on next page] (54) Title: TREATING EPHRIN RECEPTOR A2 (EPHA2) POSITIVE CANCER WITH TARGETED DOCETAXEL-GENERAT-ING NANO-LIPOSOME COMPOSITIONS FIG lA (57) Abstract: EphA2 targeted doxorubicin generating nano-liposomes are useful in the treatment of cancer overexpress-ing EphA2, alone or in combination with chemotherapeutic agents such as gemcitabine or carboplatin. Anti-EphA2 scFv-PEG-DSPE PEG-DSG , , = Lipid 4,7.4 = -= Membrane A65,6 ¨ 110 next rl V 1-1 = 0:; ',õ`is 4 ':n'tf = ." **2 Docetaxei Prodrug Internal Aqueous Space WO 2017/161071 Al 111111111111110111010101111101010111011110110101110M0HMI0V0llill Published: ¨ with sequence listing part of description (Rule 5.2(a)) ¨ with international search report (Art. 21(3))